FDA
-
-
-
-
-
-
-
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
-
-
-
-
-
-
-
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
-
-
-
-
-
-
-
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
-
-
-
-
-
-
-
Chardan Capital Markets Downgrades Seres Therapeutics (MCRB) to Neutral
-
-
-
-
-
-
-
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
-
-
-
-
-
-
-
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
-
325,303 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

